PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.

Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM) and 5EU (US, France, Germany, Italy, Spain, ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).